



## Product Specification Sheet

<b>Product Name:</b>	Necrosulfonamide (NSA)	<p><b>Necrosulfonamide (NSA)</b></p>
<b>Catalog Number:</b>	C6327-2 (powder) C6327-2s (10mM in DMSO)	
<b>Package Size:</b>	2 mg	
<b>Technical information:</b>		
Chemical Formula:	C <sub>18</sub> H <sub>15</sub> N <sub>5</sub> O <sub>6</sub> S <sub>2</sub>	
CAS #:	432531-71-0	
Molecular Weight:	461.47	
Purity:	>96%	
Formulation:	Light Yellow solid	
Solubility:	Soluble in DMSO up to 50 mM	
Chemical Name:	(E)-N-[4-[N-(3-methoxypyrazin-2-yl)sulfamoyl]phenyl]-3-(5-nitrothiophene-2-yl)acrylamide	
Storage:	Store solid powder at 4°C desiccated; Store DMSO solution at -20°C.	
<b>Handling:</b>	<ul style="list-style-type: none"><li>For C6327-2 (powder), add 0.433 mL of DMSO to make 10 mM solution.</li><li>For C6327-2s, before open the vial, centrifuge the vial at 500rpm x 1 min in a 50 mL conical tube to ensure full recovery of sample.</li></ul>	
<b>Biological Activity:</b>	<p>Necrosulfonamide (NSA) is a very specific and potent necrosis inhibitor with an IC<sub>50</sub> less than 0.2 μM. It specifically blocks necrosis downstream of receptor-interacting serine-threonine kinase 3 (RIP3) activation. RIP3 is a key signaling molecule in the programmed necrosis pathway. Treating cells with NSA arrested necrosis at a specific step at which RIP3 formed discrete punctae in cells.</p> <p>Different from Necrostatin-1, NSA does not inhibit the necrosis-induced RIP1 and RIP3 interactions. NSA targets MLKL, a critical substrate of RIP3 during induction of necrosis. It binds the N-terminal of MLKL, covalently modifies Cys86 of human MLKL, and prevents necrosome from interacting with its downstream effectors.</p>	
<b>Reference:</b>	<ol style="list-style-type: none"><li>Sun L., et al. Mixed Lineage Kinase Domain-like Protein Mediates Necrosis Signaling Downstream of RIP3 Kinase. <i>Cell</i> (2012), 148(1):213-227.</li><li>Wang Z., et al. The mitochondrial phosphatase PGAM5 functions at the convergence point of multiple necrotic death pathways. <i>Cell</i> (2012), 148(1):228-243</li></ol>	

For Technical Support: [technical@cellagentech.com](mailto:technical@cellagentech.com)

*For research use only, not for clinical or diagnostic use.*